Equities research analysts expect that OncoSec Medical Inc (NASDAQ:ONCS) will announce earnings per share of ($0.18) for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for OncoSec Medical’s earnings. OncoSec Medical posted earnings per share of ($0.28) in the same quarter last year, which indicates a positive year over year growth rate of 35.7%. The business is scheduled to issue its next earnings results on Wednesday, October 24th.

On average, analysts expect that OncoSec Medical will report full-year earnings of ($0.90) per share for the current fiscal year. For the next financial year, analysts forecast that the company will report earnings of ($0.64) per share, with EPS estimates ranging from ($0.68) to ($0.60). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that follow OncoSec Medical.

OncoSec Medical (NASDAQ:ONCS) last issued its earnings results on Wednesday, June 13th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.04).

A number of equities research analysts have commented on ONCS shares. Dawson James reiterated a “buy” rating on shares of OncoSec Medical in a research report on Monday, July 16th. Maxim Group set a $5.00 price target on OncoSec Medical and gave the company a “buy” rating in a research report on Monday, April 16th. HC Wainwright set a $4.00 price target on OncoSec Medical and gave the company a “buy” rating in a research report on Tuesday, August 7th. Finally, ValuEngine upgraded OncoSec Medical from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. OncoSec Medical has a consensus rating of “Buy” and an average price target of $4.33.

In other OncoSec Medical news, CFO Richard B. Slansky sold 84,984 shares of the company’s stock in a transaction dated Thursday, July 5th. The stock was sold at an average price of $1.39, for a total value of $118,127.76. Following the sale, the chief financial officer now owns 255,000 shares in the company, valued at approximately $354,450. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Richard B. Slansky sold 24,906 shares of the company’s stock in a transaction dated Wednesday, June 20th. The shares were sold at an average price of $1.42, for a total value of $35,366.52. Following the completion of the sale, the chief financial officer now owns 255,000 shares in the company, valued at approximately $362,100. The disclosure for this sale can be found here. Insiders sold a total of 300,106 shares of company stock worth $419,658 in the last quarter. Corporate insiders own 5.50% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ONCS. Renaissance Technologies LLC bought a new stake in shares of OncoSec Medical in the 4th quarter valued at about $272,000. Deutsche Bank AG bought a new stake in shares of OncoSec Medical during the 4th quarter valued at about $261,000. Commonwealth Equity Services LLC boosted its position in shares of OncoSec Medical by 97.6% during the 1st quarter. Commonwealth Equity Services LLC now owns 76,510 shares of the biotechnology company’s stock valued at $143,000 after purchasing an additional 37,800 shares in the last quarter. DRW Securities LLC bought a new stake in shares of OncoSec Medical during the 1st quarter valued at about $132,000. Finally, Sofinnova Ventures Inc bought a new stake in shares of OncoSec Medical during the 1st quarter valued at about $126,000. Hedge funds and other institutional investors own 26.01% of the company’s stock.

Shares of OncoSec Medical traded up $0.02, reaching $1.51, during trading on Thursday, according to MarketBeat.com. The company had a trading volume of 508,589 shares, compared to its average volume of 575,977. OncoSec Medical has a 12 month low of $0.88 and a 12 month high of $2.95.

OncoSec Medical Company Profile

OncoSec Medical Incorporated, a biotechnology company, engages in developing DNA-based intratumoral immunotherapies in the United States. The company's investigational technology, ImmunoPulseis designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as plasmid encoded IL-12 (tavokinogene telseplasmid or tavo) for the treatment of cancer.

Featured Article: Leveraged Buyout (LBO) Explained

Get a free copy of the Zacks research report on OncoSec Medical (ONCS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with MarketBeat.com's FREE daily email newsletter.